Blockage of receptor for advanced glycation end products prevents development of cardiac dysfunction in db/db type 2 diabetic mice

Jan M. Nielsen, Steen B. Kristiansen, Rikke Nørregaard, Claus L. Andersen, Larry Denner, Torsten T. Nielsen, Allan Flyvbjerg, Hans E. Bøtker

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

AimsActivation of the receptor for advanced glycation end products (RAGE) is associated with long-term complications in diabetes mellitus. In this study, we tested whether RAGE activation in the diabetic myocardium is implicated in the development of cardiac dysfunction.Methods and resultsUsing MRI and conductance catheter techniques, we evaluated cardiac function in a type 2 diabetic mouse model (db/db), and assessed the effect of blocking RAGE with a RAGE antibody. Gene expressions were evaluated in samples of myocardial tissue. Diabetic db/db mice demonstrated an accelerated age-dependent deterioration in cardiac function associated with altered expression of genes related to cardiac structure and function. Blockage of RAGE signalling prevented the reduction in systolic function (preload recruitable stroke work: 109.8 ± 13.8 vs. 94.5 ± 14.9 mmHg/μL, P = 0.04) and development of increased LV diastolic chamber stiffness (0.18 ± 0.05 vs. 0.27 ± 0.07 mmHg, P = 0.01). The cardiac expression of collagen (col1a1) was reduced by approximately 45 and the expression of myosin was switched from the foetal isoform (MHCβ) to the adult isoform(MHCα).ConclusionActivation of RAGE is a significant pathogenetic mechanism for the development of cardiac dysfunction in type 2 diabetes. The underlying mechanisms involve not only the passive biophysical properties of the myocardium but also myocyte function.

Original languageEnglish (US)
Pages (from-to)638-647
Number of pages10
JournalEuropean Journal of Heart Failure
Volume11
Issue number7
DOIs
StatePublished - Jul 2009
Externally publishedYes

Fingerprint

Myocardium
Protein Isoforms
Gene Expression
Diabetes Complications
Myosins
Muscle Cells
Type 2 Diabetes Mellitus
Advanced Glycosylation End Product-Specific Receptor
Collagen
Catheters
Stroke
Antibodies

Keywords

  • Advanced Glycation end products
  • Conductance catheter
  • db/db mice
  • Diabetic cardiomyopathy
  • Heart failure
  • RAGE

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Blockage of receptor for advanced glycation end products prevents development of cardiac dysfunction in db/db type 2 diabetic mice. / Nielsen, Jan M.; Kristiansen, Steen B.; Nørregaard, Rikke; Andersen, Claus L.; Denner, Larry; Nielsen, Torsten T.; Flyvbjerg, Allan; Bøtker, Hans E.

In: European Journal of Heart Failure, Vol. 11, No. 7, 07.2009, p. 638-647.

Research output: Contribution to journalArticle

Nielsen, JM, Kristiansen, SB, Nørregaard, R, Andersen, CL, Denner, L, Nielsen, TT, Flyvbjerg, A & Bøtker, HE 2009, 'Blockage of receptor for advanced glycation end products prevents development of cardiac dysfunction in db/db type 2 diabetic mice', European Journal of Heart Failure, vol. 11, no. 7, pp. 638-647. https://doi.org/10.1093/eurjhf/hfp070
Nielsen, Jan M. ; Kristiansen, Steen B. ; Nørregaard, Rikke ; Andersen, Claus L. ; Denner, Larry ; Nielsen, Torsten T. ; Flyvbjerg, Allan ; Bøtker, Hans E. / Blockage of receptor for advanced glycation end products prevents development of cardiac dysfunction in db/db type 2 diabetic mice. In: European Journal of Heart Failure. 2009 ; Vol. 11, No. 7. pp. 638-647.
@article{499cdeb112a440e8a520c5f9db076f22,
title = "Blockage of receptor for advanced glycation end products prevents development of cardiac dysfunction in db/db type 2 diabetic mice",
abstract = "AimsActivation of the receptor for advanced glycation end products (RAGE) is associated with long-term complications in diabetes mellitus. In this study, we tested whether RAGE activation in the diabetic myocardium is implicated in the development of cardiac dysfunction.Methods and resultsUsing MRI and conductance catheter techniques, we evaluated cardiac function in a type 2 diabetic mouse model (db/db), and assessed the effect of blocking RAGE with a RAGE antibody. Gene expressions were evaluated in samples of myocardial tissue. Diabetic db/db mice demonstrated an accelerated age-dependent deterioration in cardiac function associated with altered expression of genes related to cardiac structure and function. Blockage of RAGE signalling prevented the reduction in systolic function (preload recruitable stroke work: 109.8 ± 13.8 vs. 94.5 ± 14.9 mmHg/μL, P = 0.04) and development of increased LV diastolic chamber stiffness (0.18 ± 0.05 vs. 0.27 ± 0.07 mmHg, P = 0.01). The cardiac expression of collagen (col1a1) was reduced by approximately 45 and the expression of myosin was switched from the foetal isoform (MHCβ) to the adult isoform(MHCα).ConclusionActivation of RAGE is a significant pathogenetic mechanism for the development of cardiac dysfunction in type 2 diabetes. The underlying mechanisms involve not only the passive biophysical properties of the myocardium but also myocyte function.",
keywords = "Advanced Glycation end products, Conductance catheter, db/db mice, Diabetic cardiomyopathy, Heart failure, RAGE",
author = "Nielsen, {Jan M.} and Kristiansen, {Steen B.} and Rikke N{\o}rregaard and Andersen, {Claus L.} and Larry Denner and Nielsen, {Torsten T.} and Allan Flyvbjerg and B{\o}tker, {Hans E.}",
year = "2009",
month = "7",
doi = "10.1093/eurjhf/hfp070",
language = "English (US)",
volume = "11",
pages = "638--647",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Blockage of receptor for advanced glycation end products prevents development of cardiac dysfunction in db/db type 2 diabetic mice

AU - Nielsen, Jan M.

AU - Kristiansen, Steen B.

AU - Nørregaard, Rikke

AU - Andersen, Claus L.

AU - Denner, Larry

AU - Nielsen, Torsten T.

AU - Flyvbjerg, Allan

AU - Bøtker, Hans E.

PY - 2009/7

Y1 - 2009/7

N2 - AimsActivation of the receptor for advanced glycation end products (RAGE) is associated with long-term complications in diabetes mellitus. In this study, we tested whether RAGE activation in the diabetic myocardium is implicated in the development of cardiac dysfunction.Methods and resultsUsing MRI and conductance catheter techniques, we evaluated cardiac function in a type 2 diabetic mouse model (db/db), and assessed the effect of blocking RAGE with a RAGE antibody. Gene expressions were evaluated in samples of myocardial tissue. Diabetic db/db mice demonstrated an accelerated age-dependent deterioration in cardiac function associated with altered expression of genes related to cardiac structure and function. Blockage of RAGE signalling prevented the reduction in systolic function (preload recruitable stroke work: 109.8 ± 13.8 vs. 94.5 ± 14.9 mmHg/μL, P = 0.04) and development of increased LV diastolic chamber stiffness (0.18 ± 0.05 vs. 0.27 ± 0.07 mmHg, P = 0.01). The cardiac expression of collagen (col1a1) was reduced by approximately 45 and the expression of myosin was switched from the foetal isoform (MHCβ) to the adult isoform(MHCα).ConclusionActivation of RAGE is a significant pathogenetic mechanism for the development of cardiac dysfunction in type 2 diabetes. The underlying mechanisms involve not only the passive biophysical properties of the myocardium but also myocyte function.

AB - AimsActivation of the receptor for advanced glycation end products (RAGE) is associated with long-term complications in diabetes mellitus. In this study, we tested whether RAGE activation in the diabetic myocardium is implicated in the development of cardiac dysfunction.Methods and resultsUsing MRI and conductance catheter techniques, we evaluated cardiac function in a type 2 diabetic mouse model (db/db), and assessed the effect of blocking RAGE with a RAGE antibody. Gene expressions were evaluated in samples of myocardial tissue. Diabetic db/db mice demonstrated an accelerated age-dependent deterioration in cardiac function associated with altered expression of genes related to cardiac structure and function. Blockage of RAGE signalling prevented the reduction in systolic function (preload recruitable stroke work: 109.8 ± 13.8 vs. 94.5 ± 14.9 mmHg/μL, P = 0.04) and development of increased LV diastolic chamber stiffness (0.18 ± 0.05 vs. 0.27 ± 0.07 mmHg, P = 0.01). The cardiac expression of collagen (col1a1) was reduced by approximately 45 and the expression of myosin was switched from the foetal isoform (MHCβ) to the adult isoform(MHCα).ConclusionActivation of RAGE is a significant pathogenetic mechanism for the development of cardiac dysfunction in type 2 diabetes. The underlying mechanisms involve not only the passive biophysical properties of the myocardium but also myocyte function.

KW - Advanced Glycation end products

KW - Conductance catheter

KW - db/db mice

KW - Diabetic cardiomyopathy

KW - Heart failure

KW - RAGE

UR - http://www.scopus.com/inward/record.url?scp=67650096803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650096803&partnerID=8YFLogxK

U2 - 10.1093/eurjhf/hfp070

DO - 10.1093/eurjhf/hfp070

M3 - Article

VL - 11

SP - 638

EP - 647

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 7

ER -